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ABSTRACT
Malignant pleural mesothelioma (MPM) is an aggressive tumor that is often 
causally associated with asbestos exposure. Comparative genomic hybridization 
techniques and arrays demonstrated a complex set of copy number variations (CNVs) 
in the MPM-genome. These techniques however have a limited resolution, throughput 
and flexibility compared to next-generation sequencing platforms. 
In this study, the presence of CNVs in the MPM-genome was investigated using an 
MPM-cohort (N = 85) for which genomic microarray data are available through ‘The Cancer 
Genome Atlas’ (TCGA). To validate these results, the genomes of MPMs and matched 
normal samples (N = 21) were analyzed using low-pass whole genome sequencing on 
an ‘Illumina HiSeq’ platform. CNVs were detected using in-house developed analysis 
pipelines and frequencies of copy number loss and gain were calculated.
In both datasets, losses on chromosomes 1, 3, 4, 6, 9, 13 and 22 and gains 
on chromosomes 1, 5, 7 and 17 were found in at least 25% and 15% of MPMs, 
respectively. Besides the well-known MPM-associated genes, CDKN2A, NF2 and BAP1, 
other interesting cancer-associated genes were listed as frequently involved in a copy 
number loss (e.g. EP300, SETD2 and PBRM1). Moreover, four cancer-associated genes 
showed a high frequency of copy number gain in both datasets (i.e. TERT, FCGR2B, 
CD79B and PRKAR1A). A statistically significant association between overall survival 
and the presence of copy number loss in the CDKN2A-containing region was observed 
in the TCGA-set.
In conclusion, recurrent CNVs were detected in both datasets, occurring in regions 
harboring known MPM-associated genes and genes not previously linked to MPM. 
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a 
rare and highly aggressive cancer originating from the 
mesothelial cells of the pleura [1]. A causal relationship 
between the development of MPM and exposure to 
asbestos has been demonstrated, with up to 80% of all 
patients being professionally exposed in the 30 to 40 years 
preceding the diagnosis [2]. Due to differences in historical 
asbestos import, consumption and ban, the incidence of 
MPM greatly varies between countries worldwide, ranging 
from seven patients per million inhabitants in Japan to 40 
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patients per million inhabitants in Australia [3]. Moreover, 
since asbestos is still being used in some non-Western and 
Western countries, MPM will remain a global health issue 
for decades to come [4]. Besides this increasing incidence, 
patients diagnosed with MPM still face a poor prognosis. 
The median overall survival time of untreated patients is 
six to ten months with a 5-year survival rate below 5%. 
Furthermore, current therapeutic options are limited and 
seem to provide only modest survival benefit [5, 6].
Genetic analyses have revealed genetic alterations in 
a number of genes in MPM. Of these, somatic inactivation 
of the tumor suppressor genes CDKN2A, NF2 and BAP1 
seems to be the most prevalent [7–9]. Additionally, 
the presence of a complex and heterogeneous set of 
chromosomal copy number variations (CNVs) in MPM 
was described. Although no single MPM-specific alteration 
was observed, losses in chromosomes 1p, 4q, 9p, 13q, 14q 
and 22q were commonly noted using karyotype analyses 
and (microarray-based) comparative genomic hybridization 
techniques [10–19]. These techniques however have a 
limited resolution compared to highly sensitive next-
generation sequencing platforms, which allow genome-
wide detections in a high-throughput manner.
Here, we investigated the presence of CNVs in the 
MPM-genome using an MPM-cohort (N = 85), for which 
genomic microarray data are available through ‘The Cancer 
Genome Atlas’ (TCGA). These results were validated 
using low-pass whole genome sequencing (LP-WGS) on 
genomic DNA from paired tumor and normal samples of 
21 MPM-patients. We found recurrent CNVs in several 
regions, harboring interesting cancer-associated genes.
RESULTS
The Cancer Genome Atlas
Copy number variations in MPM
Segmented copy number data of 85 MPMs, 
available through the TCGA-website, were used to assess 
the MPM copy number profile (Table 1). In order to 
identify regions with recurrent CNVs in the 85 MPMs, 
frequencies of copy number loss and gain were calculated 
using the ‘Multi-intersect tool’ from ‘BEDtools’ (Figure 1) 
[20]. Large losses occurring in more than 25% of cases 
were identified on chromosomes 1 (p36.33-p36.13 
and p31.1-p13.1), 3 (p22.2-p14.2), 4 (q13.1-q35.2), 
6 (q14.1-q27), 9 (p22.2-p21.1), 13 (q11-q22.3), 14 
(q11.1-q32.33) and 22 (q11.1-q13.33). Some regions 
on chromosome 22 were even lost in up to 75% of all 
studied MPMs. Gains occurred less frequently, with large 
regions on chromosomes 1 (q21.2-q44), 5 (p15.33-p11), 7 
(p22.3-q11.21 and q11.21-q31.33) and 17 (q21.32-q25.1) 
exhibiting gains in more than 15% of MPMs.
In order to identify potentially interesting genes within 
regions exhibiting recurrent CNVs in the TCGA-dataset, 
the exact frequency of copy number loss and gain in the 
regions containing ‘Cancer census genes’ was listed [21]. 
The ‘top 20’ list of ‘Cancer census genes’ most frequently 
involved in a copy number loss contained some well-known 
MPM-associated genes (Table 2). Whereas NF2 was lost 
in 62% of cases, CDKN2A was lost in 51% and BAP1 
in 44% of MPMs. However, the list also contained other 
genes, some even lost in a higher frequency of samples 
(e.g. EP300, PDGFB, MKL1, MYH9, APOBEC3B and 
ZNF278). EP300 for example was located in a chromosomal 
region lost in 69% of all MPMs, being the highest reported 
frequency of copy number loss (Table 2). EP300 encodes 
an histone acetyltransferase, regulating transcription via 
chromatin remodeling and influencing cell proliferation and 
differentiation [22, 23]. The frequency of copy number gain 
in regions containing ‘Cancer census genes’ was remarkably 
lower compared to the frequency of copy number loss 
(highest frequency of gain: 27% versus loss: 69%, Table 2). 
Nevertheless, regions containing some interesting ‘Cancer 
census genes’ on chromosomes 5, 1 and 17 showed copy 
number gain in a substantial number of patients. The region 
containing TERT, the gene encoding the catalytic component 
of the telomerase enzyme [24], exhibited a copy number 
gain in up to 27% of MPMs, being the most frequently 
reported copy number gain (Table 2). 
Association with clinical and histological parameters
Associations between clinicopathological 
parameters and the presence of copy number loss 
(segment mean ≤ -0.25) or gain (segment mean ≥ 0.25) 
in the regions containing the most frequently involved 
‘Cancer census genes’ (Table 2) were investigated. When 
for a certain sample a gene was spread over multiple 
segments with different segment means, this sample was 
not considered when examining potential associations. 
No statistically significant associations with gender, 
age at diagnosis (before or after the age of 60), asbestos 
exposure or histological diagnosis (epithelioid or non-
epithelioid) were found (Supplementary Tables 1 and 2, 
depicting the p-values for the investigated associations). 
However, a statistically significant association was found 
between a survival less than 36 months and the presence 
of copy number loss in the segment containing CDKN2A 
(p-value: 0.01). Moreover, a univariate survival analysis 
showed a significantly longer survival time for patients 
with tumors without copy number loss in the segment 
containing CDKN2A (p-value: 4.54e-6, median survival 
of 982 days versus 456 days for patients with tumors 
with CDKN2A loss, Figure 2). Univariate analyses of the 
prognostic effect of gender, histologic subtype and age at 
diagnosis were not significant (p-values: 0.446; 0.0895 
and 0.382 respectively). A non-significant trend towards 
an association between age at diagnosis (younger or 
older than 60 years) and the presence of copy number 
gain in the segment containing TERT was identified 
(p-value: 0.07).
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Low-pass whole genome sequencing
Copy number variations in MPM
To validate the results we obtained via the TCGA-
dataset, 21 MPMs and matched normal samples were 
assessed for CNVs using LP-WGS (Table 1). For this 
analysis, the genome was divided in 50 kb-bins and for 
every bin, the log2-ratio comparing tumor versus normal 
sample was determined (Supplementary Figure 1, 
depicting the copy number profile of a representative 
sample pair). As in the data obtained using the TCGA-set, 
it was observed that copy number losses occurred more 
frequently in these MPMs compared to copy number gains.
In order to identify regions with recurrent CNVs in 
the 21 MPMs, two different approaches were followed. A 
first strategy was based on calculating the frequencies of 
both copy number loss and gain in each of the 50 kb-bins. 
Doing so, regions with recurrent gains and losses were 
observed (Figure 3). Large losses occurring in more than 
25% of cases were identified on parts of chromosomes 
1 (p31.1-p11.2), 3 (p22.3-p14.1), 4 (p16.3-p11 and 
q12-q35.2), 6 (q15-q27), 9 (p23-p21.1), 13 (q11-q34), 17 
(p13.3-p11.2) and 22 (q11.1-q13.33), with some regions 
being lost in up to 60% of all MPMs. Gains occurred 
less frequently, with regions less easy to demarcate on 
chromosomes 1 (q21.2-q44), 2 (p25.3-p22.3), 3 (q24-q29), 
5 (p15.33-p11 and q11.1-q35.3), 7 (p22.3-p11.2 and 
q11.21-q36.3), 15 (q21.1-q26.3), 17 (q11.2-q25.3), 18 
(p11.32-p11.21 and q11.1-q23) and 19 (p13.3-p12 and 
q11-q13.43) exhibiting gains in more than 15% of MPMs.
Similar as for the TCGA-data, the exact frequency 
of copy number gain and loss in the regions containing 
‘Cancer census genes’ was assessed [21]. In contrast to 
the TCGA-data, the ‘top 20’ list of ‘Cancer census genes’ 
most frequently involved in a copy number loss in the 
LP-WGS-data did not contain NF2, CDKN2A or BAP1 
(Table 3). These genes were lost in 48%, 52% and 43% 
of MPMs respectively, which was not enough to rank 
them in the top. Six other ‘Cancer census genes’ however, 
were listed among the most frequently lost ones, both in 
the TCGA- and LP-WGS-dataset (i.e. EP300, SETD2, 
PBRM1, CHEK2, MKL1 and MAPK1). As in the TCGA-
data, EP300 was the ‘Cancer census gene’ with the highest 
reported frequency of copy number loss, being in 71% of 
studied MPMs (Table 3). The frequency of copy number 
gain in regions containing ‘Cancer census genes’ was in 
line with that obtained in the TCGA-data and remarkably 
Table 1: Clinical characteristics of the included MPM-patients (TCGA-set and LP-WGS-set)
Patient characteristics
Absolute amount (percentage)
TCGA (N = 85) LP-WGS (N = 21)
Gender
   Male
   Female
69 (81%)
16 (19%)
19 (90%)
2 (10%)
Age at diagnosis
   Before or at the age of 60
   After the age of 60
   Unknown
32 (38%)
53 (62%)
0 (0%)
9 (43%)
10 (48%)
2 (10%)
History of asbestos exposure
   Yes
   No
   Unknown
54 (64%)
14 (16%)
17 (20%)
12 (57%)
0 (0%)
9 (43%)
Histologic diagnosis
   Epithelioid mesothelioma
   Non-epithelioid mesothelioma
   Unknown
56 (66%)
24 (28%)
5 (6%)
18 (86%)
3 (14%)
0 (0%)
Platinum/pemetrexed treatment prior to tissue collection
   No
   Yes
85 (100%)
0 (0%)
10 (48%)
11 (52%)
Time to death or last follow-up
   Less than 36 months
   More than 36 months
   Unknown
73 (86%)
11 (13%)
1 (1%)
16 (76%)
3 (14%)
2 (10%)
Vital status
   Dead
   Alive
56 (66%)
29 (34%)
15 (71%)
6 (29%)
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lower compared to the frequency of copy number loss 
(Table 3). Of the ‘Cancer census genes’ most frequently 
involved in a copy number gain, four were in common 
with those in the TCGA-data (i.e. FCGR2B, TERT, CD79B 
and PRKAR1A). PMS2, a gene encoding a component of 
the DNA mismatch repair system [25], was involved in a 
copy number gain in up to 33% of MPMs, being the most 
frequently reported copy number gain (Table 3).
A second and novel strategy to determine regions 
with recurrent CNVs in the 21 MPMs was based on 
calculating the mean log2-ratio for every 50 kb-bin over 
the 21 sample pairs (Figure 3). Although this strategy 
precludes the identification of regions exhibiting both 
losses and gains in different tumors, these regions are less 
likely to be important in MPM-tumorigenesis. As a result, 
a sharper focus on the most interesting regions is obtained. 
In order to statistically summarize this information, a one-
sample t-test was performed for every 50 kb-bin, with the 
null hypothesis assuming a mean log2-ratio of 0. In regions 
with mean log2-ratios different from 0, p-values were not 
uniformly distributed and some even shifted towards the 
significance threshold. A Kolmogorov-Smirnov (K-S) test 
was performed to confirm the non-uniform distribution 
of these p-values. Regions in which the p-value of the 
K-S test was smaller than 10–15 were listed in Table 4. 
The negative logarithm of the p-value of the K-S test was 
plotted against chromosome position (Supplementary 
Figure 2, depicting the mean copy number profile over the 
21 sample pairs). 
Association with clinical and histological parameters
Associations between clinicopathological 
parameters and the presence of copy number loss (log2-
ratio ≤ −0.25) or gain (log2-ratio ≥ 0.25) in the regions 
containing the most frequently involved ‘Cancer census 
genes’ (Table 3) were tested. No statistically significant 
Figure 1: Circos plot of the CNVs observed in array data of 85 MPMs, available through TCGA. Frequencies of copy 
number loss (red) and gain (green) are depicted for every chromosome position. 
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Table 2: ‘Cancer census genes’ most frequently involved in a copy number loss or gain in the TCGA-
data
‘Cancer census genes’ most frequently involved in a copy 
number lossa
‘Cancer census genes’ most frequently involved in a copy 
number gaina
Gene name Chromosome position
OG or 
TSb 
Frequency 
loss (%)c Gene name
Chromosome 
position
OG or 
TSb
Frequency 
gain (%)c
EP300 chr22:41,488,614-
41,576,081
/ 69.41 TERT chr5:1,253,287-
1,295,162
/ 27.06
PDGFB chr22:39,619,685-
39,640,957
OG 68.24 SDHA chr5:218,356-
256,814
TS 24.71
MKL1 chr22:40,806,292-
41,032,690
/ 68.24 DROSHA chr5:31,400,602-31,532,282 TS 23.53
MYH9 chr22:36,677,323-
36,784,063
/ 68.24 IL7R chr5:35,856,977-35,879,705 / 22.35
APOBEC3B chr22:39,378,404-39,388,784 OG/TS 64.71 LIFR
chr5:38,475,065-
38,595,507 / 22.35
ZNF278 chr22:31,721,790-31,742,249 / 63.53 FCGR2B
chr1:161,632,905-
161,648,444
/ 21.18
NF2 chr22:29,999,545-30,094,589 TS 62.35 CDC73
chr1:193,091,088-
193,223,942 TS 21.18
MN1 chr22:28,144,265-
28,197,486
/ 62.35 PTPRC chr1:198,608,098-
198,726,605
/ 20.00
CHEK2 chr22:29,083,731-29,137,822 TS 62.35 MDM4
chr1:204,485,507-
204,527,248 OG 20.00
EWSR1 chr22:29,663,998-
29,696,515
/ 62.35 ELK4 chr1:205,566,695-
205,602,000
/ 20.00
BCR chr22:23,522,552-
23,660,224
OG 60.00 SLC45A3 chr1:205,626,981-
205,649,630
/ 20.00
SMARCB1 chr22:24,129,150-
24,176,705
/ 60.00 HLF chr17:53,342,321-
53,402,426
OG 20.00
MAPK1 chr22:22,113,947-22,221,970 OG 57.65 MSI2
chr17:55,333,931-
55,757,299 / 20.00
CLTCL1 chr22:19,167,712-19,279,239 TS 55.29 RNF43
chr17:56,431,038-
56,494,931
/ 20.00
SEPT5 chr22:19,704,743-19,711,102 / 55.29 CLTC
chr17:57,697,050-
57,774,317 TS 20.00
LZTR1 chr22:21,336,558-
21,353,326
TS 55.29 PPM1D chr17:58,677,544-
58,743,640
OG 20.00
CDKN2A chr9:21,967,751-21,975,132 TS 50.59 BRIP1
chr17:59,756,547-
59,940,920 TS 20.00
SETD2 chr3:47,057,898-
47,205,467
TS 44.71 CD79B chr17:62,006,098-
62,009,704
OG 20.00
BAP1 chr3:52,435,020-52,444,121 TS 43.53 DDX5
chr17:62,494,374-
62,502,484
OG 20.00
NCKIPSD chr3:48,711,278-48,723,334 / 42.35 AXIN2
chr17:63,524,683-
63,557,740
TS 20.00
PBRM1 chr3:52,579,368-52,713,739 TS 42.35 PRKAR1A
chr17:66,507,921-
66,529,570
/ 20.00
aThe 20 ‘Cancer census genes’ most frequently involved in a copy number loss or gain were identified. However, as some 
‘Cancer census genes’ showed exactly the same frequency of loss or gain, this list can contain more than 20 genes.
bClassified as an oncogene or tumor suppressor gene according to the ‘Cancer census gene’ list. 
cWhen a ‘Cancer census gene’ was spread over multiple segments, the frequency of the segment containing the largest part 
of the gene was considered.
OG: oncogene; TS: tumor suppressor gene
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associations with gender, age at diagnosis (before or 
after the age of 60), histological diagnosis (epithelioid or 
non-epithelioid), survival (more or less than 36 months) 
or chemotherapeutic treatment before sample collection 
were found (Supplementary Tables 3 and 4, depicting the 
p-values for the investigated associations).
DISCUSSION
Recurrent CNVs are detected in TCGA- and  
LP-WGS-data
In the past, karyotype analyses and (microarray-
based) comparative genomic hybridization techniques 
have been employed to reveal the presence of a complex 
and heterogeneous set of chromosomal CNVs in MPM 
[10–19]. However, these techniques have a limited 
resolution compared to highly sensitive next-generation 
sequencing platforms. Therefore, we performed LP-
WGS on genomic DNA from 21 paired tumor and normal 
samples to validate the results we obtained using array 
data from 85 MPMs, available through TCGA.
Both in the sample set from TCGA and from LP-
WGS, chromosomal regions exhibiting frequent copy 
number loss or gain were identified (Supplementary 
Figure 3, comparing the CNVs in both sample sets). 
Losses of regions on chromosomes 1 (p31.1-p13.1), 
3 (p22.2-p14.2), 4 (q13.1-q35.2), 6 (q15-q27), 9 
(p22.2-p21.1), 13 (q11-q22.3) and 22 (q11.1-q13.33) were 
found in at least 25% of MPMs, both in the TCGA-set and 
LP-WGS-sample set. Regions with recurrent copy number 
gain occurred less frequently. Nevertheless, gains were 
detected on chromosomes 1 (q21.2-q44), 5 (p15.33-p11), 
7 (p22.3-p11.2 and q11.21-q31.33) and 17 (q21.32-q25.1) 
in more than 15% of MPMs in both sample sets. Next to 
these similarities, some differences between both sample 
sets could be noted. The most striking of these differences 
was a loss of regions on chromosomes 1 (p36.33-p36.13) 
and 14 (q11.1-q32.33) which was not present in our LP-
WGS-sample set. Moreover, some copy number gains 
identified in the LP-WGS-sample set on chromosomes 
2 (p25.3-p22.3), 3 (q24-q29), 5 (q11.1-q35.3), 18 
(p11.32-p11.21 and q11.1-q23) and 19 (p13.3-p12 and 
q11-q13.43) were not that frequent in the TCGA-data. 
These differences might be explained by the fact that the 
TCGA-set was significantly bigger than LP-WGS-set (i.e. 
85 versus 21 MPMs). Furthermore, different techniques 
with different resolutions were used to identify CNVs 
(i.e. SNP-array and LP-WGS). Whereas the ‘Affymetrix 
Genome-Wide SNP Array 6.0’ allowed the analysis 
of more than 906,600 markers for single nucleotide 
polymorphisms and more than 946,000 markers for 
CNVs (inter-marker distance below 700 bases), LP-WGS 
achieved an average genome-wide coverage of 1.21x. 
‘Cancer census genes’ are located in regions 
exhibiting recurrent CNVs
In order to identify potentially interesting genes 
within the regions exhibiting recurrent CNVs, the exact 
frequency of copy number loss and gain in the regions 
containing ‘Cancer census genes’ was determined, both for 
Figure 2: Kaplan-Meier plot of the overall survival according to the presence or absence of copy number loss in the 
chromosomal region containing CDKN2A.
Oncotarget113679www.impactjournals.com/oncotarget
the TCGA- and LP-WGS-sample set [21]. The inactivation 
of the tumor suppressor genes CDKN2A, NF2 and BAP1 
is well documented in MPM. Hence, it was no surprise 
that the regions in which these genes are located were 
frequently involved in a copy number loss in both sample 
sets. Whereas CDKN2A was lost in 51% of TCGA-samples 
and 52% of in-house samples, NF2 exhibited loss in 62% 
and 48%, and BAP1 in 44% and 43% of TCGA- and in-
house samples respectively. Although these frequencies 
were sufficient to rank these genes in the ‘top 20’ list 
of ‘Cancer census genes’ most frequently involved in a 
copy number loss in the TCGA-sample set, this was not 
the case for our in-house sample set. However, given the 
recurrent deletion of CDKN2A in MPM (in more than 50% 
of cases in both datasets), its detection could be useful in 
a diagnostic and therapeutic setting. Regarding MPM-
diagnosis, the use of fluorescence in situ hybridization 
to detect the homozygous deletion of CDKN2A proved 
helpful to distinguish between malignant mesothelial 
cells and benign reactive mesothelial cells both in pleural 
effusion and tissue samples [26, 27]. Regarding MPM-
therapy, inactivation of CDKN2A results in deregulation 
of CDK4 and CDK6, which makes MPMs good candidate 
responders to CDK4- and CDK6-inhibitory drugs. In 
hormone receptor-positive metastatic breast cancer, 
palbociclib, an inhibitor of CDK4 and CDK6, significantly 
improves progression-free survival [28]. Currently, the 
option of starting a phase II study with small molecule 
CDK-inhibitors in patients with refractory MPM is being 
investigated (NCT02187783). It should however be noted 
that also RB1 was frequently involved in a copy number 
loss in the LP-WGS-sample set. As loss of RB1-function 
Figure 3: Circos plot of the CNVs observed in low-pass whole genome data of 21 MPMs. The inner layer represents the 
frequency of copy number loss (red) and gain (green) in every 50 kb-bin. The outer layer represents the mean log2-ratio for every 50 kb-bin 
over the 21 tumor/normal sample pairs. Mean log2-ratios smaller than -0.10 or bigger than 0.10 are depicted in red or green respectively.
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Table 3: ‘Cancer census genes’ most frequently involved in a copy number loss or gain in the 
LP-WGS-data
‘Cancer census genes’ most frequently involved in a copy number lossa ‘Cancer census genes’ most frequently involved in a copy number gaina
Gene name Chromosome position OG or TSb
Frequency loss 
(%)c Gene name Chromosome position
OG or 
TSb
Frequency 
gain (%)c
EP300 chr22:41,488,614-
41,576,081
/ 71.43 PMS2 chr7:6,012,870-
6,048,737
/ 33.33
SETD2 chr3:47,057,898-
47,205,467
TS 66.67 FCGR2B chr1:161,632,905-
161,648,444
/ 23.81
PBRM1 chr3:52,579,368-52,713,739 TS 66.67 EIF4A2
chr3:186,501,361-
186,507,685
/ 23.81
ROS1 chr6:117,609,530-117,747,018 OG 66.67 TERT
chr5:1,253,287-
1,295,162
/ 23.81
ZNF198 chr13:20,532,810-
20,665,968
/ 66.67 HNRNPA2B1 chr7:26,229,556-
26,240,413
/ 23.81
RB1 chr13:48,877,883-
49,056,026
TS 66.67 EGFR chr7:55,086,725-55,275,031 / 23.81
CHEK2 chr22:29,083,731-29,137,822 TS 66.67 MET
chr7:116,312,459-
116,438,440
OG 23.81
TRIM33 chr1:114,935,399-115,053,781 / 61.90 RAD21
chr8:117,858,173-
117,887,105 / 23.81
CACNA1D chr3:53,529,076-
53,846,492
OG 61,90 KLF6 chr10:3,818,188-3,827,473 / 23.81
FLT3 chr13:28,577,411-
28,674,729
OG 61.90 NAB2 chr12:57,482,677-57,489,259 OG 23.81
FOXO1 chr13:41,129,801-41,240,734 OG/TS 61.90 MLLT6
chr17:36,861,873-
36,886,056
/ 23.81
MKL1 chr22:40,806,292-
41,032,690
/ 61.90 CIC chr19:42,788,817-42,799,949 OG/TS 23.81
EPS15 chr1:51,819,935-51,984,995 / 57.14 FAM131B
chr7:143,050,493-
143,059,840 / 19.05
WHSC1 chr4:1,873,123-1,983,934 / 57.14 PLAG1 chr8:57,073,468-57,123,859 OG 19.05
PTPN13 chr4:87,515,468-
87,736,328
TS 57.14 CHCHD7 chr8:57,124,315-
57,131,176
/ 19.05
RAP1GDS1 chr4:99,182,527-
99,365,012
/ 57.14 RECQL4 chr8:145,736,667-145,743,210 / 19.05
FBXW7 chr4:153,242,410-
153,456,185
/ 57.14 NUTM2B chr10:81,462,983-81,472,513 / 19.05
FAT1 chr4:187,508,937-
187,644,987
TS 57.14 NUTM2A chr10:88,985,205-88,994,733 / 19.05
NFIB chr9:14,081,842-14,314,045 / 57.14 ETNK1
chr12:22,778,076-
22,843,608
/ 19.05
MLLT3 chr9:20,344,968-
20,622,514
OG 57.14 DICER1 chr14:95,552,565-
95,608,085
TS 19.05
BRCA2 chr13:32,889,617-32,973,809 TS 57.14 CD79B
chr17:62,006,098-
62,009,704
OG 19.05
LHFP chr13:39,917,029-
40,177,356
/ 57.14 PRKAR1A chr17:66,507,921-
66,529,570
/ 19.05
LCP1 chr13:46,700,058-
46,756,459
/ 57.14 ZNF521 chr18:22,641,888-22,932,214 / 19.05
MAPK1 chr22:22,113,947-22,221,970 OG 57.14
aThe 20 ‘Cancer census genes’ most frequently involved in a copy number loss or gain were identified. However, as some ‘Cancer census 
genes’ showed exactly the same frequency of loss or gain, this list can contain more than 20 genes.
bClassified as an oncogene or tumor suppressor gene according to the ‘Cancer census gene’ list.
cFor ‘Cancer census genes’ smaller than 50 kb, the frequency of copy number loss or gain in the 50 kb-region containing at least 90% of the 
gene was considered. ‘Cancer census genes’ smaller than 50 kb, that were not located for at least 90% in one bin, were excluded from this 
analysis. For the analysis of ‘Cancer census genes’ bigger than 50 kb, additional bins with the exact chromosomal location of these genes 
were analyzed.
OG: oncogene; TS: tumor suppressor gene
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Table 4: Chromosomal regions showing copy number loss or gain in LP-WGS-dataset
Copy number loss Copy number gain
Chromosome Chromosomal region Chromosome Chromosomal region
1 p31.1-p11.2
1
q25.3-q32.2
3 p22.3-p14.1 q32.3-q42.13
4
p16.3-p16.1 q42.13-q43
p16.1-p15.1 q43-q44
p15.1-p12
2
p15-p14
q13.1-q25 p14-p13.3
q26-q28.1 q22.2-q22.3
q28.1-q28.3 q22.3-q23.3
q31.1-q31.21 q24.1-q24.2
q31.21-q35.1 q31.1
6
q14.3-q15 q31.3-q32.1
q16.1-q21 q32.1-q32.3
q21-q27
3
q12.1-q13.13
9
p22.2-p21.2 q13.13-q13.31
q21.2-q21.31 q21.1-q21.2
q21.31-q22.1 q21.3-q22.1
q22.31-q22.32 q24-q26.1
10
q23.1 q26.1-q26.33
q23.31-q23.33 q26.33-q28
q24.2-q24.31
5
p15.33-p15.2
q25.1 p15.2-q11.1
11
q21-q22.1 6 p25.3-p25.2
q22.3-q23.1
7
p22.1-p13
q23.1-q23.2 p13-p11.2
13 q11-q34 q11.23-q21.12
17 p13.3-p11.2 q21.13-q21.3
22 q11.1-q13.31 q31.1-q31.31
q32.2-q33
8
q12.1
q21.13
q21.3-q22.3
12
q14.1-q15
q15-q21.1
15
q21.3-q22.31
q22.31-q23
18
p11.32-p11.31
p11.31-p11.21
q12.1
q12.2-q12.3
q12.3-q21.1
q21.1-q21.2
q21.2-q21.31
q21.31-q21.32
q21.33-q22.1
q22.2-q23
20
q13.12-q13.13
q13.2-q13.32
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is reported to be a mechanism of resistance to CDK-
inhibitors, a subset of MPMs might have to be excluded 
from trials aiming at proving the efficacy of CDK-
inhibitors in MPM [29]. 
Both in the TCGA- and LP-WGS-sample set, other 
interesting cancer-associated genes were listed as being 
frequently involved in a copy number loss (Tables 2 
and 3). Strikingly, both sample sets shared six genes in 
their ‘top 20’ list of most frequently lost ‘Cancer census 
genes’ (i.e. EP300, SETD2, PBRM1, CHEK2, MKL1 
and MAPK1). EP300, in both sample sets the ‘Cancer 
census gene’ with the highest reported frequency of 
copy number loss, encodes an histone acetyltransferase, 
important in cell proliferation and differentiation [22, 23]. 
EP300 has been reported to play a role in tumorigenesis, 
and inactivating mutations in EP300 have been 
described in several solid tumor types (e.g. colorectal 
and gastric tumors) [30]. However, not much is known 
about the role of EP300 in MPM. SETD2, encoding a 
member of the SET-domain family containing histone 
methyltransferases [31], and PBRM1, encoding a subunit 
of ATP-dependent chromatin remodeling complexes [32], 
have been recently linked to MPM. Not only mutations, 
gene fusions and splice alterations were described, also 
frequent minute deletions were found in these genes 
[19, 33, 34]. Moreover, silencing of SETD2 or PBRM1 
was found to increase proliferation in a mesothelioma 
cell line [34]. Regarding the cancer-associated genes 
CHEK2, encoding a cell cycle checkpoint regulator; 
MKL1, encoding a protein amongst others involved in 
transducing signals from the cytoskeleton to the nucleus; 
and MAPK1, encoding an essential component of the MAP 
kinase signal transduction pathway, not much is known 
about their role in MPM. Yet, one study did report that a 
substantial amount of miRNAs, downregulated in MPM, 
targeted MAPK1, which might suggest that this molecule 
is overexpressed in MPM, in contrast to our results [35].
Although in both sample sets the frequency of copy 
number gain in regions containing ‘Cancer census genes’ 
was remarkably lower compared to the frequency of copy 
number loss, some interesting genes were among the 
most frequently gained ones (Tables 2 and 3). Moreover, 
both sample sets shared four genes in their ‘top 20’ list 
of ‘Cancer census genes’ most frequently involved in a 
copy number gain (i.e. TERT, FCGR2B, CD79B and 
PRKAR1A). TERT, the ‘Cancer census gene’ exhibiting 
the most frequent copy number gain in the TCGA-
set, encodes the catalytic component of the telomerase 
enzyme. Telomerase expression is normally repressed in 
postnatal somatic cells resulting in progressive shortening 
of the telomeres. However, deregulation of telomerase 
expression in somatic cells can contribute to a replicative 
immortality, which is one of the ‘Hallmarks of Cancer’ 
[36]. In line with this function, TERT expression was 
detected in 99% of MPMs using immunohistochemistry 
and in situ hybridization [37]. Furthermore, TERT mRNA 
was found to be upregulated in MPM. Nonetheless, this 
upregulation was reported to be the result of mutations 
in the TERT promoter and not of gene copy number 
amplification [38]. Regarding the cancer-associated genes 
FCGR2B, encoding a low affinity receptor for the Fc-
region of immunoglobulin gamma complexes; CD79B, 
encoding the immunoglobulin beta protein which is 
necessary for functioning of the B-cell antigen receptor; 
and PRKAR1A, encoding one of the regulatory subunits of 
the cAMP-dependent protein kinase, not much is known 
about their role in MPM. Strikingly, PMS2, the ‘Cancer 
census gene’ most frequently involved in a copy number 
gain in the LP-WGS-set, was not ranked among the most 
frequently gained genes in the TCGA-set. As this gene 
encodes a component of the DNA mismatch repair system 
[25], one would not expect a copy number gain of the 
region containing this gene. However, overexpression of 
PMS2 was previously reported to confer genetic instability 
and DNA-damage tolerance in prostate cancer [39, 40].
Regarding these results, it should be noted that the 
‘Cancer census genes’ that are most frequently involved 
in a copy number loss or gain, are clustered in certain 
regions (Tables 2 and 3). For example, a substantial 
amount of the most lost genes in the TCGA-dataset are 
located on chromosome 22. As chromosome 22 is almost 
entirely lost in more than 60% of MPMs in this dataset, 
this is no surprise. Obviously, not all listed genes will 
be equally important in MPM-tumorigenesis, and some 
genes will only be listed as they are in the proximity of 
more important ones. This might explain why even some 
oncogenes (e.g. MAPK1) pop up. Only further functional 
studies can elucidate the role of each of the listed genes in 
the pathogenesis of MPM.
CDKN2A loss is associated with a shorter overall 
survival
In the LP-WGS-set, no statistically significant 
associations between any of the investigated 
clinicopathological parameters and the presence of copy 
number loss or gain in regions with selected ‘Cancer 
census genes’ were found (Supplementary Tables 3 and 4, 
depicting the p-values for the investigated associations). 
In the TCGA-set however, a statistically significant 
association was found between an overall survival 
shorter than 36 months and the presence of copy number 
loss in the chromosomal segment containing CDKN2A, 
which was confirmed by a univariate survival analysis 
(Supplementary Table 1 and Figure 2). Differences in 
prognosis according to CDKN2A deletion status and 
CDKN2A (p16ink4a/p14ARF) protein expression 
were previously reported [41–45]. In several reports, a 
statistically significant survival advantage was found 
for patients with tumors without CDKN2A homozygous 
deletion [41, 42, 45]. Moreover, in studies by Dacic et al. 
and Kobayashi et al., loss of CDKN2A (p16ink4a) protein 
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expression, as detected by immunohistochemistry, was 
shown to be associated with a poor prognosis. Whereas 
Dacic et al. also reported significant differences in 
survival according to the homozygous deletion status of 
CDKN2A, this was not mirrored by Kobayashi et al. [42, 
43]. In a study by Walter et al., a survival difference was 
seen between patients with a low CDKN2A (p14ARF) 
mRNA-expression and patients with a high expression. 
Nevertheless, the association between overall survival 
and CDKN2A (p14ARF) mRNA-expression did not reach 
statistical significance [44]. Given the limited therapeutic 
options for MPM-patients, their modest benefit and 
sometimes substantial toxicity, identifying patients with 
a particularly poor prognosis can be beneficial. Hence, 
the potential utility of CDKN2A deletion in a prognostic 
setting holds promise for the future.
MATERIALS AND METHODS
TCGA-data collection 
TCGA is a joint effort of the National Cancer 
Institute (NCI) and the National Human Genome Research 
Institute (NHGRI), that has generated comprehensive 
maps of the key genomic changes in 33 types of cancer 
(http://cancergenome.nih.gov/). Regarding MPM, TCGA 
holds data of 87 patients, including segmented copy 
number data (TCGA level 3 data, hg19.seg-files). For 
the latter, the original data files were generated using 
the ‘Affymetrix Genome-Wide SNP Array 6.0’ (Thermo 
Fisher Scientific, Waltham, MA, USA), and the files were 
analyzed using the ‘CopyNumberInferencePipeline’ in 
‘GenePattern’ [46]. In each of the resulting files, segment 
means were normalized against a panel of several 
thousands of blood normal samples. Patient characteristics 
of the TCGA-patients are summarized in Table 1. Two 
patients in the TCGA MPM-cohort received neo-adjuvant 
treatment, whereas all others did not. Therefore, we chose 
to exclude these two patients from all analyses.
Copy number profiling of TCGA-data
In order to identify recurrent copy number 
differences in the MPM-samples of which segmented copy 
number data were available through TCGA, frequencies 
of copy number loss and gain were calculated. In this 
respect, regions with segment means smaller or equal 
than -0.25 were considered as losses and regions with 
segment means bigger or equal than 0.25 were considered 
as gains. Using the ‘Multi-intersect tool’ from ‘BEDtools’ 
[20], chromosomal regions with recurrent copy number 
loss or gain in the 85 MPMs were identified, after 
which frequencies were calculated. In order to identify 
potentially interesting genes within regions exhibiting 
recurrent CNVs, the frequency of copy number loss and 
gain specifically in the regions containing ‘Cancer census 
genes’ was determined. The ‘Cancer census genes’ are 
genes with substantial published evidence in oncology. 
This list, containing 609 genes at the time of first analysis 
(accessed in November 2016), is regularly updated by the 
COSMIC team and can be found on their website [21].
Patient samples collection and preparation
In order to validate the results obtained using 
TCGA-data, LP-WGS was performed on an independent 
MPM-cohort. This study was conducted with the approval 
of the ethical committee of the Antwerp University 
Hospital and the University of Antwerp (Reference 
numbers 14/8/73 & 16/23/248). Twenty-one MPM- and 
matched normal samples were obtained from the tumor 
bank of the Antwerp University Hospital (Biobank@UZA, 
Antwerp, Belgium; ID: BE71030031000, Belgian Virtual 
Tumorbank funded by the National Cancer Plan) and 
from the tissue bank of the Erasmus University Medical 
Center Rotterdam. Patient characteristics are summarized 
in Table 1. Non-tumor material consisted of cryopreserved 
blood lymphocytes, collected before or after surgery. 
When matched blood samples were not available, healthy 
lung or pleura tissue, removed during resection, was used. 
All tissue samples were collected in the operating room, 
immediately snap-frozen in liquid nitrogen and stored at 
–80°C. Diagnosis and tumor content were confirmed by 
histological examination of hematoxylin-eosin-stained 
5 µm-sections. Histology of the tumor samples included 
epithelioid (N = 18), biphasic (N = 2) and epithelioid/
desmoplastic (N = 1). DNA was extracted from each of 
the blood samples and from fifteen 10 µm-sections per 
tissue sample using the ‘QIAamp DNA Mini Kit’ (Qiagen, 
Hilden, Germany, Cat. No. 51304), according to the 
manufacturer’s instructions.
Copy number profiling of LP-WGS-data
Genomic DNA was fragmented using a Covaris 
instrument (Covaris, Woburn, MA, USA) and sequencing 
libraries were generated using the ‘KAPA Library 
Preparation Kit’ (Roche, Basel, Switzerland, Cat. No. 
KK8230). Next, sample libraries were sequenced on an 
‘Illumina HiSeq 1500 platform’ (Illumina, San Diego, CA, 
USA) in high output mode, generating 2 × 100 bp paired-
end reads. This resulted in an average coverage of 1.21x, 
which enabled the detection of structural variants.
Sequencing reads were adapter trimmed and mapped 
to the UCSC human genome (GRCh37/hg19). The 
presence of CNVs in the samples was analyzed using in-
house developed analysis pipelines. The algorithm divides 
the genome into non-overlapping 50 kb-bins and counts 
all mapped sequencing reads for each tumor and normal 
sample within each bin. After correction of read counts for 
local GC-content using lowess normalization, log2-ratios 
were calculated for every tumor and normal sample pair. 
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In order to identify recurrent copy number 
differences between tumor and normal samples, 
frequencies of copy number loss and gain were 
calculated for each of the 50 kb-bins. We used a log2-
ratio threshold of -0.25 for chromosomal losses and 0.25 
for copy number gains. Similar as for the TCGA-data, 
the frequency of copy number loss and gain specifically 
in the regions containing ‘Cancer census genes’ was 
assessed [21]. For ‘Cancer census genes’ smaller than 
50 kb, the frequency of copy number loss and gain in 
the 50 kb-region containing at least 90% of the gene 
was considered. ‘Cancer census genes’ smaller than 50 
kb, that were not located for at least 90% in one bin, 
were excluded from this analysis. To enable the analysis 
of ‘Cancer census genes’ bigger than 50 kb, additional 
bins with the exact chromosomal location of these genes 
were analyzed. Next to this frequency-based approach, 
the mean log2-ratio for each 50 kb-bin over the 21 sample 
pairs was determined. This is a novel approach enabling 
the identification of recurrent copy number differences 
between tumor and normal samples. Within each of the 
50 kb-bins, a one-sample t-test was carried out, testing 
the null hypothesis that the mean log2-ratio within this 
bin equals 0. If all null hypotheses are true across all 
bins tested, it is expected that the p-values of these tests 
follow a uniform distribution with boundaries 0 and 
1. This latter hypothesis was tested using the K-S test. 
One K-S test was carried out per sliding window of 50 
p-values (coming from the one-sample t-test). The step 
width between the sliding windows was set to 25.
Statistical analysis
To identify associations between clinicopathological 
parameters on the one hand and the presence of copy 
number loss or gain in regions containing selected genes 
on the other hand, a Pearson’s Chi-squared test with 
Yates’ continuity correction was performed. In case more 
than 20% of the cells had an expected count below five, 
a Fisher’s Exact test was used. Segment means (TCGA-
data) and log2-ratios (LP-WGS-data) smaller or equal than 
-0.25 were considered as losses and values bigger or equal 
than 0.25 were considered as gains. 
Parameters such as the presence of copy number 
loss or gain in regions containing selected genes, gender 
and histological subtype, were tested for association with 
overall survival using the log-rank test. In this respect, 
overall survival was defined as the time from initial 
pathologic diagnosis to the date of death or last follow-up. 
Survival curves were plotted using the method of Kaplan 
and Meier. 
All p-values were based on a two-sided hypothesis, 
with p-values smaller or equal than 0.05 considered 
statistically significant. Decimal values were rounded 
to the nearest digit. Statistical analyses were carried out 
using the statistical software ‘R’ version 2.3.1. [47].
CONCLUSIONS
Recurrent copy number losses and gains were 
identified in the TCGA-set and confirmed in an in-
house sample set using LP-WGS. These CNVs occurred 
in regions harboring cancer-associated genes that are 
potentially useful in a diagnostic, therapeutic and 
prognostic setting. 
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